Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
Latest action · Nov 21, 2019 Ordered to be Reported (Amended).
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJul 25, 2019
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
This bill limits in certain instances the number of patents that the manufacturer of a biologic drug can assert in a lawsuit against a company seeking to sell a biosimilar version of that drug. (A biologic drug is produced through natural processes or isolated from natural sources. A biosimilar version is substantially similar to the original biologic, which is the reference product, and is often marketed as a less expensive alternative.)
The bill's provisions apply to an existing framework that gives the biosimilar manufacturer an abbreviated path to Food and Drug Administration approval to sell the biosimilar. Specifically, if the biosimilar manufacturer completes certain actions under the framework, such as sharing certain information about its product with the reference product manufacturer, the bill limits the number of certain patents that the reference product manufacturer may assert in a lawsuit, such as patents that were filed more than four years after the reference product received market approval. The limit shall not apply to patents claiming certain methods for using the biologic drug.
The court in which the infringement lawsuit is filed may increase the limit if justice so requires or if there is good cause for the increase.
Cosponsors 1
Members who signed on, in the order they did. All signed on Jul 25, 2019.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-AL | Martha Roby | Original | Jul 25, 2019 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Judiciary Committee | Referred Jul 25, 2019Markup Nov 21, 2019 |
| Courts, Intellectual Property, Artificial Intelligence, and the Internet Subcommittee | Referred Aug 28, 2019Discharged Nov 19, 2019 |
Actions 6
Everything that happened, newest first.
- Nov 21, 2019Committee Consideration and Mark-up Session Held.
- Nov 21, 2019Ordered to be Reported (Amended).
- Nov 19, 2019Subcommittee on Courts, Intellectual Property, and the Internet Discharged.
- Aug 28, 2019Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
- Jul 25, 2019Introduced in House
- Jul 25, 2019Referred to the House Committee on the Judiciary.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 165, no. 126, July 25, 2019, page H7469.
CRS reports 2
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 2
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R46741 | Drug Pricing and Intellectual Property: The Legislative Landscape for the 117th Congress | Report | Mar 31, 2021 |
| R46221 | Drug Pricing and Pharmaceutical Patenting Practices Archived | Report | Feb 11, 2020 |
Related bills 3
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 1416 | Affordable Prescriptions for Patients Act of 2019 | Related bill | Jun 28, 2019 |
| HR 2486 | FUTURE Act | Related bill | Jul 23, 2020 |
| HR 2884 | Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act | Reintroduced Bill | Sep 30, 2021 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend title 35, United States Code, to clarify and improve the process for subsection (k) applicants to resolve patent infringement claims for biological products (commonly known as the "patent dance"), and for other purposes.
- Short Title(s) as Introduced
- Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
Subjects
Assigned by the Library of Congress. Policy area: Commerce.
Text 1
Each version as it was printed, newest first.
- Jul 25, 2019Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.